Core Viewpoint - The company Fu Yuan Pharmaceutical (601089.SH) has received a drug registration certificate from the National Medical Products Administration for its product, Pioglitazone Metformin Tablets (15mg/850mg), allowing for its production [1] Group 1: Product Approval - The National Medical Products Administration has issued a drug registration certificate for Pioglitazone Metformin Tablets (15mg/850mg) [1] - The product is indicated for type 2 diabetes patients who have inadequate blood sugar control with Metformin alone or those currently using a combination of Pioglitazone and Metformin [1] Group 2: Market Context - The original manufacturer of the drug is Takeda Pharmaceutical Company, which received approval for the product in the United States in August 2005 [1] - The original manufacturer's version of Pioglitazone Metformin Tablets has not yet been launched in China [1]

吡格列酮二甲双胍片(15mg/850mg)的原研企业是武田药品工业株式会社，2005年8月获美国批准上市。 目前，原研厂家的吡格列酮二甲双胍片尚未在中国上市。本品适用于在饮食控制和运动的基础上，用于 目前使用盐酸吡格列酮和盐酸二甲双胍联合治疗的2型糖尿病患者或单用盐酸二甲双胍治疗后血糖控制 不佳的2型糖尿病患者。 福元医药（601089）(601089.SH)发布公告，近日，公司收到了国家药品监督管理局(以下简称"国家药监 局")颁发的吡格列酮二甲双胍片(15mg/850mg)(规格：每片含盐酸吡格列酮15mg(以C H N O S计)和盐酸 二甲双胍850mg)(以下简称"该药品")《药品注册证书》(证书编号：2025S02764)，批准该药品生产。 ...